Canagliflozin (Hemihydrate): A High-Purity SGLT2 Inhibitor for Diabetes Mellitus and Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate) is a chemically defined, water-insoluble small molecule SGLT2 inhibitor with a molecular weight of 453.52 g/mol and high purity (≥98%) verified by HPLC and NMR (APExBIO). It selectively inhibits renal sodium-glucose co-transporter 2 (SGLT2), promoting urinary glucose excretion and enabling mechanistic studies of glucose homeostasis (ifg-1.com). Recent peer-reviewed screening confirms that canagliflozin does not inhibit the mTOR pathway at research-relevant concentrations (GeroScience 2025). Canagliflozin is supplied by APExBIO for research use only, not for diagnostic or medical application. Its robust solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) supports diverse experimental workflows.

Biological Rationale

Canagliflozin (hemihydrate) belongs to the canagliflozin drug class, specifically targeting sodium-glucose co-transporter 2 (SGLT2) expressed primarily in the renal proximal tubules. SGLT2 is responsible for reabsorbing 90% of filtered glucose in the kidney. Inhibition of SGLT2 disrupts this process, leading to increased urinary glucose excretion and reduced blood glucose levels—an established therapeutic approach in type 2 diabetes research (APExBIO). This mechanism enables precise study of glucose homeostasis pathways and metabolic disorder models. Unlike molecules acting on mTOR or other pathways, canagliflozin's selectivity allows for focused interrogation of renal glucose handling and its metabolic consequences (Advanced Insights for SGLT2 Inhibition). This article extends prior reviews by clarifying the absence of mTOR pathway overlap, which improves experimental specificity.

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) acts as a competitive, reversible inhibitor of SGLT2. By binding to the SGLT2 transporter on the luminal surface of proximal tubule epithelial cells, it blocks glucose reabsorption from the renal filtrate. This leads to a dose-dependent increase in urinary glucose excretion, reduction of plasma glucose, and secondary effects on body weight and insulin sensitivity in animal models (Advanced Insights into SGLT2 Inhibition). Notably, canagliflozin does not significantly inhibit SGLT1 at concentrations relevant for in vitro and in vivo research, minimizing off-target effects (APExBIO). Its mechanism is independent of insulin secretion or sensitivity, supporting its use in diverse diabetes mellitus research contexts. This mechanistic precision is critical for dissecting glucose homeostasis without confounding effects from mTOR or other signaling pathways.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) demonstrates ≥98% purity by HPLC and NMR in APExBIO's C6434 kit, supporting reproducibility in metabolic disorder research (APExBIO).
• Solubility is ≥83.4 mg/mL in DMSO and ≥40.2 mg/mL in ethanol at 25°C, but it is insoluble in water (APExBIO).
• Canagliflozin does not inhibit the mTOR pathway at concentrations up to 100 μM in yeast-based screening, confirming pathway specificity (Breen et al. 2025, DOI).
• Its SGLT2 inhibitory activity is validated in cell-based and animal models, with robust effects on glucose excretion under controlled conditions (Mechanistic Precision and Selectivity).
• Canagliflozin is stable at -20°C with blue ice shipping; solutions should be used promptly and not stored long-term to preserve efficacy (APExBIO).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is widely applied in:

• Glucose metabolism research, especially in diabetes mellitus and metabolic disorder models.
• Studies dissecting renal glucose reabsorption inhibition and its systemic effects.
• Translational research targeting the glucose homeostasis pathway in preclinical systems.

This article updates and extends prior analyses by explicitly clarifying the compound's lack of mTOR inhibitory activity—a key point for experimenters designing pathway-specific studies (Mechanistic Precision). For a deeper pathway-specific experimental design context, see Advanced Insights for SGLT2 Inhibition; this article provides the latest screening results and solubility data.

Common Pitfalls or Misconceptions

• Not an mTOR inhibitor: Peer-reviewed evidence shows no mTOR pathway inhibition at concentrations up to 100 μM (Breen et al. 2025).
• Not intended for diagnostic or therapeutic use: Supplied strictly for scientific research (see APExBIO product page).
• Water insolubility: Ineffective in aqueous buffers; must be dissolved in DMSO or ethanol at appropriate concentrations.
• Short-term solution stability: Do not store prepared solutions long-term; use immediately to avoid degradation.
• Not a broad SGLT family inhibitor: Selectivity for SGLT2 over SGLT1 minimizes off-target effects, but this must be considered in experimental design.

Workflow Integration & Parameters

Preparation: Dissolve canagliflozin (hemihydrate) in DMSO (≥83.4 mg/mL) or ethanol (≥40.2 mg/mL) at room temperature. For in vitro assays, further dilute into culture media; for in vivo studies, dissolve in vehicle compatible with experimental design. Storage: Store powder at -20°C; minimize freeze-thaw cycles. Solution use: Prepare fresh aliquots for each experiment; avoid long-term solution storage due to potential degradation (APExBIO).

Shipping: APExBIO ships with blue ice to maintain compound integrity. Purity and validation: Each lot is validated by HPLC and NMR for ≥98% purity, supporting reproducibility in metabolic disorder research. For more on advanced workflow strategies, see Redefining Translational Research, which this article extends with new pathway validation data.

Conclusion & Outlook

Canagliflozin (hemihydrate) from APExBIO is a rigorously validated, high-purity SGLT2 inhibitor optimized for glucose metabolism research. Its mechanistic selectivity, chemical stability, and robust solubility in organic solvents enable reliable study of renal glucose reabsorption inhibition in metabolic and diabetes mellitus models. Critically, canagliflozin shows no mTOR pathway activity at relevant concentrations, allowing for unambiguous interpretation of glucose homeostasis experiments (Breen et al. 2025). As metabolic disorder research advances, canagliflozin (hemihydrate) remains a cornerstone reagent for pathway-specific investigation and translational study design.